HPA029981

antibody from Atlas Antibodies

Targeting: SMARCA2 BAF190, BRM, hBRM, hSNF2a, SNF2, SNF2L2, SNF2LA, Sth1p, SWI2

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

HPA029981

Provider

Atlas Antibodies

Proper citation

Atlas Antibodies Cat#HPA029981, RRID:AB_10602406

Product name

Anti-SMARCA2

Antibody type

Polyclonal

Description

Polyclonal Antibody against Human SMARCA2, Gene description: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2, Alternative Gene Names: BAF190, BRM, hBRM, hSNF2a, SNF2, SNF2L2, SNF2LA, Sth1p, SWI2, Validated applications: ICC, IHC, Uniprot ID: P51531, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 µl

Concentration

0.2 mg/ml

Storage

Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Handling

The antibody solution should be gently mixed before use.

References

Submitted references

Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report

Dong W, Dai A, Wu Z, Wang J, Wu T, Du Y, Tian W, Zheng J, Zhang Y, Wang H, Cai J, Dong S, Zhou Y, Li S, Xiao Z
Frontiers in Immunology 2024;15

---

SMARCB1 Loss in Poorly Differentiated Chordomas Drives Tumor Progression

Walhart T, Vacca B, Hepperla A, Hamad S, Petrongelli J, Wang Y, McKean E, Moksa M, Cao Q, Yip S, Hirst M, Weissman B
The American Journal of Pathology 2023;193(4):456-473

---

Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss

Zhu X, Fu Z, Chen S, Ong D, Aceto G, Ho R, Steinberger J, Monast A, Pilon V, Li E, Ta M, Ching K, Adams B, Negri G, Choiniere L, Fu L, Pavlakis K, Pirrotte P, Avizonis D, Trent J, Weissman B, Klein Geltink R, Morin G, Park M, Huntsman D, Foulkes W, Wang Y, Huang S
Nature Communications 2023;14(1)

---

Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma

Lorenzo-Guerra S, Codina-Martínez H, Suárez-Fernández L, Cabal V, García-Marín R, Riobello C, Vivanco B, Blanco-Lorenzo V, Sánchez-Fernández P, López F, Llorente J, Hermsen M
Cells 2023;13(1):81

---

SMARCA4 biology in alveolar rhabdomyosarcoma

Bharathy N, Cleary M, Kim J, Nagamori K, Crawford K, Wang E, Saha D, Settelmeyer T, Purohit R, Skopelitis D, Chang K, Doran J, Kirschbaum C, Bharathy S, Crews D, Randolph M, Karnezis A, Hudson-Price L, Dhawan J, Michalek J, Ciulli A, Vakoc C, Keller C
Oncogene 2022;41(11):1647-1656

---

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

Cantley J, Ye X, Rousseau E, Januario T, Hamman B, Rose C, Cheung T, Hinkle T, Soto L, Quinn C, Harbin A, Bortolon E, Chen X, Haskell R, Lin E, Yu S, Del Rosario G, Chan E, Dunlap D, Koeppen H, Martin S, Merchant M, Grimmer M, Broccatelli F, Wang J, Pizzano J, Dragovich P, Berlin M, Yauch R
Nature Communications 2022;13(1)

---

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo

Kofink C, Trainor N, Mair B, Wöhrle S, Wurm M, Mischerikow N, Roy M, Bader G, Greb P, Garavel G, Diers E, McLennan R, Whitworth C, Vetma V, Rumpel K, Scharnweber M, Fuchs J, Gerstberger T, Cui Y, Gremel G, Chetta P, Hopf S, Budano N, Rinnenthal J, Gmaschitz G, Mayer M, Koegl M, Ciulli A, Weinstabl H, Farnaby W
Nature Communications 2022;13(1)

---

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, Carson S, Chang Y, Wang X, Zhang Y, Vo J, Kregel S, Simko S, Delekta A, Jaber M, Zheng H, Apel I, McMurry L, Su F, Wang R, Zelenka-Wang S, Sasmal S, Khare L, Mukherjee S, Abbineni C, Aithal K, Bhakta M, Ghurye J, Cao X, Navone N, Nesvizhskii A, Mehra R, Vaishampayan U, Blanchette M, Wang Y, Samajdar S, Ramachandra M, Chinnaiyan A
Nature 2021;601(7893):434-439

---

The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes

Suzuki H, Huang S, Ng K, Chang I, Chang C, Chao Y, Chang S, Chen M, Yeh T, Chen T
PLOS ONE 2021;16(1):e0245356

---

Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients

Armon S, Hofman P, Ilié M
Cells 2021;10(8):1920

---

SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines

Ehrenhöfer-Wölfer K, Puchner T, Schwarz C, Rippka J, Blaha-Ostermann S, Strobl U, Hörmann A, Bader G, Kornigg S, Zahn S, Sommergruber W, Schweifer N, Zichner T, Schlattl A, Neumüller R, Shi J, Vakoc C, Kögl M, Petronczki M, Kraut N, Pearson M, Wöhrle S
Scientific Reports 2019;9(1)

---

Successful treatment with nivolumab for SMARCA4‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report

Naito T, Umemura S, Nakamura H, Zenke Y, Udagawa H, Kirita K, Matsumoto S, Yoh K, Niho S, Motoi N, Aokage K, Tsuboi M, Ishii G, Goto K
Thoracic Cancer 2019;10(5):1285-1288

---

Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma

Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, O'Neill R, Solomides C, Peiper S, Testa J, Uzzo R, Yang H
Oncotarget 2017;8(23):37423-37434

---

Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities

Yoshida A, Kobayashi E, Kubo T, Kodaira M, Motoi T, Motoi N, Yonemori K, Ohe Y, Watanabe S, Kawai A, Kohno T, Kishimoto H, Ichikawa H, Hiraoka N
Modern Pathology 2017;30(6):797-809

---

Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas

Karnezis A, Hoang L, Coatham M, Ravn S, Almadani N, Tessier-Cloutier B, Irving J, Meng B, Li X, Chow C, McAlpine J, Kuo K, Mao T, Djordjevic B, Soslow R, Huntsman D, Blake Gilks C, Köbel M, Lee C
Modern Pathology 2016;29(3):302-314

---

Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type

Jelinic P, Schlappe B, Conlon N, Tseng J, Olvera N, Dao F, Mueller J, Hussein Y, Soslow R, Levine D
Modern Pathology 2016;29(1):60-66

---

Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma

Samant R, Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, Liao L, Cho E, O'Neill R, Solomides C, Peiper S, Testa J, Uzzo R, Yang H
PLOS ONE 2016;11(10):e0164554

---

Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type

Karnezis A, Wang Y, Ramos P, Hendricks W, Oliva E, D'Angelo E, Prat J, Nucci M, Nielsen T, Chow C, Leung S, Kommoss F, Kommoss S, Silva A, Ronnett B, Rabban J, Bowtell D, Weissman B, Trent J, Gilks C, Huntsman D
The Journal of Pathology 2015;238(3):389-400

---

Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome

Van Houdt J, Nowakowska B, Sousa S, van Schaik B, Seuntjens E, Avonce N, Sifrim A, Abdul-Rahman O, van den Boogaard M, Bottani A, Castori M, Cormier-Daire V, Deardorff M, Filges I, Fryer A, Fryns J, Gana S, Garavelli L, Gillessen-Kaesbach G, Hall B, Horn D, Huylebroeck D, Klapecki J, Krajewska-Walasek M, Kuechler A, Lines M, Maas S, MacDermot K, McKee S, Magee A, de Man S, Moreau Y, Morice-Picard F, Obersztyn E, Pilch J, Rosser E, Shannon N, Stolte-Dijkstra I, Van Dijck P, Vilain C, Vogels A, Wakeling E, Wieczorek D, Wilson L, Zuffardi O, van Kampen A, Devriendt K, Hennekam R, Vermeesch J
Nature Genetics 2012;44(4):445-449

Immunocytochemistry

Supportive validation

Submitted by

Atlas Antibodies (provider)

Main image

Experimental details

Immunofluorescent staining of human cell line U-2 OS shows localization to nucleoplasm & vesicles.

Sample type

Human